C-MER Eye Care Holdings Limited (3309) AI Stock Analysis

• Market Cap: HK$2.26B
• Dividend Yield: 1.12%
• Average Volume (3M): 692.01K
• Price to Earnings (P/E): 33.9
• Beta (1Y): 1.11
• Revenue Growth: -0.56%
• EPS Growth: -323.09%
• Country: HK
• Employees: 2,041
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): -0.11
• Shares Outstanding: 1,255,560,900
• 10 Day Avg. Volume: 825,611
• 30 Day Avg. Volume: 692,007
• PEG Ratio: 0.05
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 41.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.00
• Price Target Upside: 12.99% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$2.00 ▲(12.99%Upside)

C-MER Eye Care Holdings Limited faces significant financial challenges with negative growth and profitability, impacting its overall score. Technical analysis provides some mixed, yet neutral signals, which slightly balances the negative valuation aspects. The absence of earnings call data and corporate events means these factors do not influence the score.

C-MER Eye Care Holdings Limited Business Overview & Revenue Model

Company Description

C-MER Eye Care Holdings Limited is a leading eye care services provider in Hong Kong and China, specializing in comprehensive ophthalmic services. The company operates a network of eye care centers offering a wide range of services including cataract surgery, myopia control, glaucoma treatment, and other specialized eye treatments. C-MER Eye Care is dedicated to providing high-quality medical care with advanced technology and a team of experienced ophthalmologists.

How the Company Makes Money

C-MER Eye Care Holdings Limited generates revenue primarily through the provision of medical services at its network of eye care centers. Key revenue streams include fees for surgical procedures such as cataract and refractive surgeries, consultation fees for ophthalmic diagnostics and treatments, and sales of optical products. The company's financial performance is supported by its strategic location in high-demand areas, a strong reputation for quality care, and partnerships with various healthcare providers and suppliers. Additionally, C-MER Eye Care may benefit from collaborations with technology firms to enhance its service offerings and maintain competitive pricing.

C-MER Eye Care Holdings Limited Financial Statement Overview

Summary

C-MER Eye Care Holdings Limited is experiencing financial challenges, with declining profitability and cash flow in 2024. The company maintains a strong equity position and low leverage, but negative growth in revenue and net income raises concerns. Immediate attention is needed on profitability and cash flow generation.

Income Statement

C-MER Eye Care Holdings Limited shows a mixed performance. The gross profit margin for 2024 is approximately 31.2%, indicating a decline from the previous year's 32.2%. The net profit margin turned negative in 2024 at -7.1%, down from 3.2% in 2023, reflecting a significant drop in profitability. Revenue growth is negative at -0.6% from 2023 to 2024. The EBIT margin is negative at -3.5% in 2024, down from 6.2% in 2023, and the EBITDA margin also decreased from 18.7% to 10.9%.

Balance Sheet

The company maintains a relatively stable equity position with an equity ratio of approximately 64.4% in 2024. The debt-to-equity ratio is 0.25, indicating a conservative leverage approach. However, return on equity has turned negative in 2024 at -7.7%, contrasting with a positive ROE of 3.4% in 2023, highlighting recent challenges in generating returns for shareholders.

Cash Flow

C-MER Eye Care Holdings Limited faced challenges with cash flow in 2024. Operating cash flow and free cash flow are reported as zero, which is concerning compared to the positive free cash flow of 245 million in 2023. This suggests potential issues with cash generation and management, impacting the company's ability to fund operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.91B	1.92B	1.73B	1.11B	699.54M
Gross Profit	527.62M	618.96M	365.34M	309.44M	163.65M
EBITDA	209.18M	359.88M	194.31M	177.80M	126.69M
Net Income	-135.16M	62.00M	-21.88M	21.86M	-6.25M
Balance Sheet
Total Assets	2.72B	2.75B	2.90B	1.96B	1.63B
Cash, Cash Equivalents and Short-Term Investments	467.25M	557.42M	698.51M	442.36M	553.93M
Total Debt	437.79M	362.99M	452.49M	471.69M	244.97M
Total Liabilities	830.24M	755.35M	903.45M	618.63M	331.98M
Stockholders Equity	1.75B	1.85B	1.87B	1.33B	1.29B
Cash Flow
Free Cash Flow	123.58M	245.30M	100.63M	19.18M	-233.39M
Operating Cash Flow	283.12M	361.15M	191.86M	148.41M	104.03M
Investing Cash Flow	-174.72M	-245.37M	-210.65M	-392.72M	-157.94M
Financing Cash Flow	-194.92M	-242.88M	281.64M	78.10M	322.37M

C-MER Eye Care Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Positive. The current price of 1.77 is below the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.75, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.57 is Neutral, neither overbought nor oversold. The STOCH value of 45.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3309.

C-MER Eye Care Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2219	75 Outperform	HK$2.16B	9.78	8.35%	2.99%	0.61%	-15.89%
1846	69 Neutral	HK$962.52M	12.07	7.39%	2.76%	0.20%	-36.95%
Sector *	60 Neutral	HK$17.07B	5.63	-7.44%	2.87%	11.55%	-28.15%
3309	52 Neutral	HK$2.26B	33.92	-7.51%	1.12%	-0.56%	-323.09%

C-MER Eye Care Holdings Limited Corporate Events

C-MER Medical Holdings Announces Board Restructuring

C-MER Medical Holdings Limited has announced a new structure for its board of directors and committees, effective from June 1, 2025. This restructuring includes appointments of key individuals to various roles, which is expected to enhance the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder engagement positively.

C-MER Medical Holdings Announces Leadership Restructuring

C-MER Medical Holdings Limited announced significant changes in its leadership structure, with Dr. Lam Shun Chiu Dennis resigning as Chairman, Executive Director, and CEO to focus on clinical work and ophthalmic innovation. Despite his resignation, Dr. Lam will continue to contribute to the company as an ophthalmologist and senior advisor. The company also appointed Dr. Ko Wing Man as an independent non-executive director and vice chairman, and Mr. Li Ling Cheung Raymond as an independent non-executive director, enhancing its board with experienced professionals. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.

C-MER Eye Care Holdings Reports Successful AGM with Strong Shareholder Support

C-MER Eye Care Holdings Limited, a company incorporated in the Cayman Islands, announced the successful passing of all resolutions at its Annual General Meeting held on 19 May 2025. The resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of executive directors, and granting of mandates for share repurchase and issuance. The results indicate strong shareholder support, with all resolutions receiving over 98% approval. This outcome reflects positively on the company’s governance and strategic direction, potentially reinforcing investor confidence.